Biotech Values

[ghmm]

While Astrue's criticisms of the FDA in this piece center around Ebola he does speak more generally and for the second time makes a highly critical and (especially coming from a lawyer) possible libelous charge:

A recent example of the FDA’s indefensible inconsistencies is its October decision to demand more data yet again—without clear, science-based standards—for companies seeking approval for several new drugs that should be available now to patients with the fatal disease of Duchenne muscular dystrophy. What makes the muscular dystrophy pronouncements worse is that there are signs that they are driven by the FDA’s worst cultural tendencies: retaliation behind closed doors, “leveling the playing field” for competing companies by slowing down the company in the lead, and improperly relying on outside advisers with a strong financial interest in the outcome of its decisions.[emphasis added] As the new Congress establishes its oversight priorities, this shameful mess should be high on its list.

One would almost think he is lobbying for a SRPT position (CEO/Chairman would be nice)